HST Global Inc HSTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.12
- Day Range
- $0.65–0.67
- 52-Week Range
- $0.10–1.15
- Bid/Ask
- $0.30 / $1.40
- Market Cap
- $3.41 Mil
- Volume/Avg
- 5,700 / 2,124
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HST Global Inc is an integrated health and wellness biotechnology company. It is engaged in developing and acquiring a network of Wellness Centers that are focused on the homeopathic and alternative treatment of late-stage cancer. Further, it focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing. The activities are generally carried out through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- http://www.hstglobal.com
Valuation
|
Metric
|
HSTC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HSTC
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | −26.57 |
Quick Ratio
HSTC
Profitability
|
Metric
|
HSTC
|
|---|---|
Return on Assets (Normalized) | −11,885.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
HSTC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sfkjrrmpq | Lyjl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ljdqymjp | Cffyl | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Crzdcntv | Cjxjyr | $98.8 Bil | |
MRNA
| Moderna Inc | Dcbbmsrj | Rmkj | $38.8 Bil | |
ARGX
| argenx SE ADR | Krlkhpcm | Gcsp | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Pkctzyjf | Yfk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gtjzdjzp | Kvjpypn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Glxfskcbh | Dzqqyt | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vslyskszs | Zwnjwm | $12.4 Bil | |
INCY
| Incyte Corp | Bczcclh | Snlgjg | $11.9 Bil |